Danaher Co. (NYSE:DHR) is Duncker Streett & Co. Inc.’s 9th Largest Position

Duncker Streett & Co. Inc. cut its stake in shares of Danaher Co. (NYSE:DHR) by 3.2% in the 4th quarter, Holdings Channel reports. The fund owned 52,501 shares of the conglomerate’s stock after selling 1,719 shares during the quarter. Danaher accounts for approximately 2.2% of Duncker Streett & Co. Inc.’s portfolio, making the stock its 9th biggest position. Duncker Streett & Co. Inc.’s holdings in Danaher were worth $12,052,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. FMR LLC raised its stake in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. Van ECK Associates Corp raised its stake in Danaher by 6,862.7% during the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after acquiring an additional 916,513 shares during the last quarter. Proficio Capital Partners LLC raised its stake in Danaher by 29,287.7% during the 4th quarter. Proficio Capital Partners LLC now owns 588,929 shares of the conglomerate’s stock valued at $135,189,000 after acquiring an additional 586,925 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares during the last quarter. Finally, Fisher Funds Management LTD purchased a new stake in Danaher during the 4th quarter valued at approximately $120,718,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Performance

Danaher stock opened at $207.73 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The stock has a fifty day moving average of $224.58 and a two-hundred day moving average of $244.92. The company has a market capitalization of $148.47 billion, a price-to-earnings ratio of 39.34, a PEG ratio of 2.66 and a beta of 0.83. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the business earned $2.09 earnings per share. On average, analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.62%. Danaher’s dividend payout ratio (DPR) is presently 24.24%.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. dropped their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Guggenheim assumed coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 target price on the stock. Citigroup dropped their target price on Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Jefferies Financial Group dropped their target price on Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research report on Wednesday, January 29th. Finally, Wells Fargo & Company dropped their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.